SCHEMBL7222707

SCHEMBL7222707

CC(C)(C)NCCn1ccc(NC(=O)c2c[nH]c3c2-c2ncccc2CCC3)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4D Q08499 1/20 0.31
CHRM1 P11229 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM3 P20309 1/20 0.31
BUB1 O43683 1/20 0.31
GRM5 P41594 1/20 0.31
EGFR P00533 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RET P07949 3/20 0.31
KDR P35968 3/20 0.31
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31
CYP2C9 P11712 1/20 0.31
SYK P43405 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7218337 0.95 GCK (0.33) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7222958 0.92 NPSR1 (0.34) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7218258 0.90 GCK (0.33) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7223214 0.90 NPSR1 (0.34) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7223026 0.88 GCK (0.33) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7218419 0.87 GCK (0.40) GCKNPSR1CHRM1CHRM2CHRM4
SCHEMBL7217066 0.87 GCK (0.40) GCKNPSR1CHRM1CHRM2CHRM4
SCHEMBL7221707 0.87 GCK (0.32) GCKNPSR1
SCHEMBL7218239 0.87 GCK (0.33) GCKNPSR1LMNAPDE4BPDE4D
SCHEMBL7216130 0.86 GCK (0.36) GCKNPSR1CHRM1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed